Before bringing a therapy to trials in patients, it must first be tested for safety and effectiveness in animals. Performing these pre-clinical studies for stem cell-based products present added challenges since many represent novel therapeutic approaches that have never been tried in humans. At the March 6th CIRM-hosted Staying on the Critical Path Workshop, Joy Cavagnaro, president of Access BIO, provides CIRM-funded scientists advice about optimizing these studies.
Stem Cell Clinical Trials: Designing Preclinical Studies for First in Human Trials | Joy Cavagnaro
Learn about California's progress toward stem cell therapies